{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:51:24Z","timestamp":1648767084573},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T00:00:00Z","timestamp":1237420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s11255-009-9556-7","type":"journal-article","created":{"date-parts":[[2009,3,18]],"date-time":"2009-03-18T16:30:55Z","timestamp":1237393855000},"page":"341-355","source":"Crossref","is-referenced-by-count":1,"title":["Direct renin inhibitors: ONTARGET for success?"],"prefix":"10.1007","volume":"41","author":[{"given":"Yasmin","family":"Pasha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gusbeth-Tatomir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,19]]},"reference":[{"key":"9556_CR1","doi-asserted-by":"crossref","unstructured":"Yusuf S, Teo K, Porge J et al (2008) Telmisartan, ramipril or both in patients at high risk for vascular events (ONTARGET Trial) NEJM 358:1547\u20131159","DOI":"10.1056\/NEJMoa0801317"},{"key":"9556_CR2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547\u2013553","journal-title":"Lancet"},{"key":"9556_CR3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11255-008-9490-0","volume":"41","author":"M Dalla Vestra","year":"2009","unstructured":"Dalla Vestra M, Simioni N, Masiero A (2009) Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy. Int Urol Nephrol 41:119\u2013126","journal-title":"Int Urol Nephrol"},{"key":"9556_CR4","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"JP Casas","year":"2005","unstructured":"Casas JP, Chua W, Loukogeorgakis S et al (2005) Effect of inhibitors of the renin angiotensin system and other antihypertensive drugs on renal outcomes; systematic review and meta-analysis. Lancet 366:2026\u20132033","journal-title":"Lancet"},{"key":"9556_CR5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","volume":"49","author":"P Sarafidis","year":"2007","unstructured":"Sarafidis P, Khosla N, Bakri GL (2007) Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49:12\u201326","journal-title":"Am J Kidney Dis"},{"key":"9556_CR6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11255-007-9211-0","volume":"39","author":"A Covic","year":"2007","unstructured":"Covic A, Gusbeth-Tatomir P, Goldsmith DJA (2007) Current dilemmas in inhibiting the renin-angiotensin system: do not forget real life. Int Urol Nephrol 39:571\u2013576","journal-title":"Int Urol Nephrol"},{"key":"9556_CR7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11906-004-0053-1","volume":"6","author":"GL Bakris","year":"2004","unstructured":"Bakris GL (2004) Clinical Importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep 6:352\u2013356","journal-title":"Curr Hypertens Rep"},{"key":"9556_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. Study Investigators. N Engl J Med 342:145\u2013153","journal-title":"N Engl J Med"},{"key":"9556_CR9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","volume":"45","author":"H Ibsen","year":"2005","unstructured":"Ibsen H, Olsen MH, Wachtell K et al (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198\u2013202","journal-title":"Hypertension"},{"key":"9556_CR10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851\u2013860","journal-title":"N Engl J Med"},{"key":"9556_CR11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7326\/0003-4819-118-2-199301150-00009","volume":"118","author":"BL Kasiske","year":"1993","unstructured":"Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF (1993) Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med 118:129\u2013138","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"9556_CR12","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/s00592-005-0180-4","volume":"42","author":"AH Barnett","year":"2005","unstructured":"Barnett AH (2005) Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol 42(Suppl 1):S42\u2013S49","journal-title":"Acta Diabetol"},{"issue":"Suppl 2","key":"9556_CR13","first-page":"B54","volume":"23","author":"RO Estacio","year":"2000","unstructured":"Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2):B54\u2013B64","journal-title":"Diabetes Care"},{"key":"9556_CR14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.jhh.1001982","volume":"20","author":"J Karalliedde","year":"2006","unstructured":"Karalliedde J, Viberti G (2006) Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 20:239\u2013253","journal-title":"J Hum Hypertens"},{"key":"9556_CR15","doi-asserted-by":"crossref","unstructured":"Jafar TH, Schmid CH, Landa M et al for the ACE inhibition in progressive renal disease study group (2001) Angiotensin converting enzyme inhibitors and progression of non diabetic renal disease: a meta-analysis of patient level data. Ann Intern Med 135:73\u201387","DOI":"10.7326\/0003-4819-135-2-200107170-00007"},{"key":"9556_CR16","doi-asserted-by":"crossref","unstructured":"The GISEN Group (1997) Randomised placebo-controlled trial of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuria, non diabetic nephropathy. Lancet 349:1857\u20131863","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"9556_CR17","unstructured":"Wright JT Jr, Bakris G, Green T et al for the American study of Kidney disease, Hypertension Study Group (2002) Effect of Blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease; results from the AASK trial. JAMA 228:2421\u20132431"},{"key":"9556_CR18","doi-asserted-by":"crossref","unstructured":"Monster TBM, Janssen WMT, de Jong PE, den Berg LTG, for the PREVEND Study Group (2002) The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population. Br J Clin Pharmacol 53:31\u201336","DOI":"10.1046\/j.0306-5251.2001.01503.x"},{"key":"9556_CR19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0272-6386(84)80083-9","volume":"3","author":"G Sugino","year":"1984","unstructured":"Sugino G, Barg AP, O\u2019Connor ST (1984) Renal perfusion is preserved during cardioselective beta blockade with metoprolol in hypertension. Am J Kidney Dis 3:357\u2013361","journal-title":"Am J Kidney Dis"},{"key":"9556_CR20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1185\/03007999109111662","volume":"12","author":"H Tindall","year":"1991","unstructured":"Tindall H, Urquhart S, Stickland M et al (1991) Treatment with atenolol prevents progression of microalbuminuria in type 1 diabetic patients. Curr Med Res Opin 12:516\u2013520","journal-title":"Curr Med Res Opin"},{"key":"9556_CR21","first-page":"1417","volume":"10","author":"G Nyugen","year":"2002","unstructured":"Nyugen G, Delarue F, Burckle C et al (2002) Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 10:1417\u20131427","journal-title":"J Clin Invest"},{"issue":"7","key":"9556_CR22","first-page":"S149","volume":"8","author":"HR Brunner","year":"1990","unstructured":"Brunner HR, Nussberger J, Weber B (1990) Various approaches to blockade of renin-angiotensin system: persistent renin response. J Hypertens 8(7):S149\u2013S153","journal-title":"J Hypertens"},{"key":"9556_CR23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","volume":"32","author":"NK Hollenberg","year":"1998","unstructured":"Hollenberg NK, Fisher ND, Price DA (1998) Pathways for angiotensin II generation in intact human tissue; evidence from comparative pharmacological interruption of the renin system. Hypertension 32:387\u2013392","journal-title":"Hypertension"},{"key":"9556_CR24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/01.HYP.26.4.602","volume":"26","author":"NK Hollenberg","year":"1995","unstructured":"Hollenberg NK, Fisher NDL (1995) Renal circulation and blockade of the renin-angiotensin system. Hypertension 26:602\u2013609","journal-title":"Hypertension"},{"key":"9556_CR25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1523-1755.2005.00145.x","volume":"67","author":"G Wolf","year":"2005","unstructured":"Wolf G, Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67:799\u2013812","journal-title":"Kidney Int"},{"key":"9556_CR26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2005.02.016","volume":"106","author":"RM Wal Van der","year":"2006","unstructured":"Van der Wal RM, Plokker HW, Lok DJ et al (2006) Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 106:367\u2013372","journal-title":"Int J Cardiol"},{"key":"9556_CR27","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE et al (2003) Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63:1791\u20131800","journal-title":"Kidney Int"},{"key":"9556_CR28","first-page":"597","volume":"17","author":"M Iglarz","year":"2004","unstructured":"Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL (2004) Involvement of oxidative stress in the profibrotic action of aldosterone; interaction with the renin angiotensin system. Am J Hypertens 17:597\u2013603","journal-title":"Am J Hypertens"},{"key":"9556_CR29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14656566.8.5.529","volume":"8","author":"VG Athyros","year":"2007","unstructured":"Athyros VG, Mikhailides DP, Kakafika AI, Tziomalos K, Karagiannis A (2007) Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 8:529\u2013535","journal-title":"Expert Opin Pharmacother"},{"key":"9556_CR30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM197203022860901","volume":"286","author":"HR Brunner","year":"1972","unstructured":"Brunner HR, Laragh JH, Baer L et al (1972) Essential hypertension, renin, aldosterone, heart attacks, strokes. N Engl J Med 286:441\u2013449","journal-title":"N Engl J Med"},{"key":"9556_CR31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","volume":"25","author":"A Villamil","year":"2007","unstructured":"Villamil A, Chrysant SG, Calhoun D et al (2007) Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25:217\u2013225","journal-title":"J Hypertens"},{"key":"9556_CR32","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1097\/01.ASN.0000146686.35541.29","volume":"15","author":"M Azizi","year":"2004","unstructured":"Azizi M, Menard J, Bissery A, Bura-Riviere A, Vaidyanathan S, Camisasca RP (2004) Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15:3126\u20133133","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl","key":"9556_CR33","first-page":"118","volume":"25","author":"C Kilo","year":"2006","unstructured":"Kilo C, Taylor A, Tschoepe D (2006) Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes. Eur Heart J 25(Suppl):118 [Abstract P789]","journal-title":"Eur Heart J"},{"issue":"Suppl","key":"9556_CR34","first-page":"119","volume":"25","author":"J Pool","year":"2006","unstructured":"Pool J, Gradman A, Kolloch R (2006) Aliskiren, a novel renin inhibitor, provides long term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. Eur Heart J 25(Suppl):119 [Abstract P790]","journal-title":"Eur Heart J"},{"key":"9556_CR35","unstructured":"Mitchell J, Oh B, Herron J et al (2006) Once daily aliskiren provides effective smooth 24 hour blood pressure control in patients with hypertension. J Clin Hypertens 8 (Suppl A):A93(P-209)"},{"key":"9556_CR36","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","volume":"39","author":"J Nussberger","year":"2002","unstructured":"Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II suppression in humans by orally active renin inhibitor aliskiren (SP100): comparison with enalapril. Hypertension 39:E1\u2013E8","journal-title":"Hypertension"},{"key":"9556_CR37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.hjh.0000202812.72341.99","volume":"24","author":"M Azizi","year":"2006","unstructured":"Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24:243\u2013256","journal-title":"J Hypertens"},{"key":"9556_CR38","unstructured":"Tekturna (aliskiren) prescribing information. Available at http:\/\/www.fda.gov"},{"key":"9556_CR39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.5414\/CPP43527","volume":"43","author":"W Dieterle","year":"2005","unstructured":"Dieterle W, Corynen S, Vaidyanathan S et al (2005) Pharmacokinetic interactions of oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 43:527\u2013535","journal-title":"Int J Clin Pharmacol Ther"},{"key":"9556_CR40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.2004.02160.x","volume":"58","author":"W Dieterle","year":"2004","unstructured":"Dieterle W, Corynen S, Mann J (2004) Effect of oral renin inhibitor aliskiren, on pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Pharmacol 58:433\u2013436","journal-title":"Br J Pharmacol"},{"key":"9556_CR41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000179573.91016.3f","volume":"46","author":"B Pilz","year":"2005","unstructured":"Pilz B, Shagdarsuren E, Wellner M et al (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46:569\u2013576","journal-title":"Hypertension"},{"key":"9556_CR42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1517\/14740338.5.5.631","volume":"5","author":"H Cheng","year":"2006","unstructured":"Cheng H, Harris RC (2006) Potential side effects of renin inhibitors-mechanisms based on comparison with other renin-angiotensin blockers. Expert Opin Drug Saf 5:631\u2013641","journal-title":"Expert Opin Drug Saf"},{"key":"9556_CR43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/01.HYP.17.4.510","volume":"17","author":"P Cordero","year":"1991","unstructured":"Cordero P, Fisher ND, Moore TJ et al (1991) Renal and endocrine responses to a renin inhibitor enalkiren, in normal humans. Hypertension 17:510\u2013516","journal-title":"Hypertension"},{"key":"9556_CR44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.HYP.23.1.44","volume":"23","author":"NDL Fisher","year":"1994","unstructured":"Fisher NDL, Allan D, Kifor I et al (1994) Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension 23:44\u201351","journal-title":"Hypertension"},{"key":"9556_CR45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0009-9236(95)90160-4","volume":"57","author":"NDL Fisher","year":"1995","unstructured":"Fisher NDL, Hollenberg NK (1995) Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther 57:342\u2013348","journal-title":"Clin Pharmacol Ther"},{"key":"9556_CR46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00005344-199308000-00010","volume":"22","author":"A-IK El-Amrani","year":"1993","unstructured":"El-Amrani A-IK, Menard J, Gonzales MF, Michel JB (1993) Effects of blocking the angiotensin II receptor, converting enzyme and renin activity on the renal hemodynamics of normotensive guinea pigs. J Cardiovasc Pharmacol 22:231\u2013239","journal-title":"J Cardiovasc Pharmacol"},{"key":"9556_CR47","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.HYP.25.5.935","volume":"25","author":"NDL Fisher","year":"1995","unstructured":"Fisher NDL, Allan DR, Gaboury CL, Hollenberg NK (1995) Intrarenal angiotensin II formation in humans. Evidence from renin inhibition. Hypertension 25:935\u2013939","journal-title":"Hypertension"},{"issue":"Suppl A","key":"9556_CR48","first-page":"A80","volume":"8","author":"DL Feldman","year":"2006","unstructured":"Feldman DL, Persohn E, Schutz H et al (2006) Renal localisation of the renin inhibitor aliskiren. J Clin Hypertens 8(Suppl A):A80","journal-title":"J Clin Hypertens"},{"key":"9556_CR49","doi-asserted-by":"crossref","unstructured":"Kapoor S (2008) Aliskiren: a rapidly, expanding role in the management of recalcitrant hypertension and renal disease. Int Urol Nephrol 40(4):1115\u20131116","DOI":"10.1007\/s11255-008-9471-3"},{"key":"9556_CR50","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11255-008-9424-x","volume":"40","author":"KC Siamopoulos","year":"2008","unstructured":"Siamopoulos KC, Kalaitzidis RG (2008) Inhibition of the renin-angiotensin system and chronic kidney disease. Int Urol Nephrol 40:1015\u20131025","journal-title":"Int Urol Nephrol"},{"key":"9556_CR51","doi-asserted-by":"crossref","unstructured":"Recio-Mayoral A, Kaski JC, McMurray JJ et al (2007) Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc Drugs Ther 21(6):459\u2013465","DOI":"10.1007\/s10557-007-6069-4"},{"key":"9556_CR52","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","volume":"49","author":"BH Oh","year":"2007","unstructured":"Oh BH, Mitchell J, Herron JR et al (2007) Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49:1157\u20131163","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"9556_CR53","first-page":"299","volume":"27","author":"M Weir","year":"2006","unstructured":"Weir M, Bush C, Zhang J, Keefe D, Satlin A (2006) Antihypertensive efficacy and benefits of oral renin inhibitor aliskiren in patients with hypertension. A pooled analysis. Eur Heart J 27(Suppl):299 [Abstract 1796]","journal-title":"Eur Heart J"},{"key":"9556_CR54","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/ndt\/gfm363","volume":"22","author":"L Segall","year":"2007","unstructured":"Segall L, Covic A, Goldsmith DJA (2007) Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol Dial Transplant 22:2435\u20132439","journal-title":"Nephrol Dial Transplant"},{"key":"9556_CR55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","volume":"361","author":"N Nakao","year":"2003","unstructured":"Nakao N, Yoshimura A, Morita H et al (2003) Combination treatment of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised control trial. Lancet 361:117\u2013124","journal-title":"Lancet"},{"key":"9556_CR56","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","volume":"63","author":"R Campbell","year":"2003","unstructured":"Campbell R, Sangalli F, Pertucci E et al (2003) Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chorionic nephropathies. Kidney Int 63:1094\u20131103","journal-title":"Kidney Int"},{"key":"9556_CR57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/HJH.0b013e3280113950","volume":"25","author":"H Krum","year":"2007","unstructured":"Krum H, Gilbert E (2007) Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J Hypertens 25:25\u201335","journal-title":"J Hypertens"},{"issue":"Suppl","key":"9556_CR58","first-page":"117","volume":"25","author":"MA Munger","year":"2006","unstructured":"Munger MA, Drummond W, Essop MR (2006) Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur Heart J 25(Suppl):117 [Abstract: P784]","journal-title":"Eur Heart J"},{"key":"9556_CR59","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","volume":"42","author":"A Stanton","year":"2003","unstructured":"Stanton A, Jensen C, Nussberger J, O\u2019Brien E (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42:1137\u20131143","journal-title":"Hypertension"},{"key":"9556_CR60","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","volume":"111","author":"A Gradman","year":"2005","unstructured":"Gradman A, Schmieder RE, Lins RL et al (2005) Aliskiren, a novel orally effective renin inhibitor, provides dose dependent antihypertensive efficacy and placebo like tolerability in hypertensive patients. Circulation 111:1012\u20131018","journal-title":"Circulation"},{"key":"9556_CR61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","volume":"20","author":"JL Pool","year":"2007","unstructured":"Pool JL, Schmeider RE, Azizi M et al (2007) Aliskiren an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 20:11\u201320","journal-title":"Am J Hypertens"},{"key":"9556_CR62","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/00005344-199911000-00008","volume":"34","author":"JP Clozel","year":"1999","unstructured":"Clozel JP, V\u00e9niant MM, Qiu C, Sprecher U, Wolfgang R, Fischli W (1999) Renal vascular and biochemical responses to systemic renin inhibition in dogs at low renal perfusion pressure. J Cardiovasc Pharmacol 34:674\u2013682","journal-title":"J Cardiovasc Pharmacol"},{"key":"9556_CR63","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ndt\/15.5.637","volume":"15","author":"P Paasen Van","year":"2000","unstructured":"Van Paasen P, de Zeeuw D, Navis G, de Jong PE (2000) Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 15:637\u2013643","journal-title":"Nephrol Dial Transplant"},{"key":"9556_CR64","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"Parving HH, Persson F, Lewis JB et al (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433\u20132446","journal-title":"N Engl J Med"},{"key":"9556_CR65","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ki.2008.68","volume":"73","author":"F Persson","year":"2008","unstructured":"Persson F, Rossing P, Schjoedt KJ et al (2008) Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 73:1419\u20131425","journal-title":"Kidney Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-009-9556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-009-9556-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-009-9556-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T11:55:29Z","timestamp":1559390129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-009-9556-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,19]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9556"],"URL":"https:\/\/doi.org\/10.1007\/s11255-009-9556-7","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,19]]}}}